The CFRI CF Community Voices Podcast

Understanding Gastrointestinal Cancers in Cystic Fibrosis – Christine Hachem, MD (Audio)

Dr. Christine Hachem, Professor of Medicine in the Division of Gastroenterology at Saint Louis University, presents an overview on GI cancers with cystic fibrosis. With improvements in therapies for CF, there has been an increase in GI cancers in people with CF, the most common of which is colorectal cancer. Dr. Hachem details the epidemiology, etiology and risk factors for GI cancers in CF, as well as current screening recommendations. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Role of CFTR Arginine-933 in Channel Function and Potentiator Binding and Efficacy – Stephen Aller, PhD (Audio)

Dr. Stephen Aller, Associate Professor at the Department of Pharmacology and Toxicology at the University of Birmingham in Alabama, presents results from CFRI-funded research on the role of CFTR Arginine-933 in folding, gating and potentiator drug binding. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Follow-Up Q&A on Partnership in CF Care: Complementary Therapies – Hanna Phan, PharmD, FCCP, FPPA (Audio)

At Dr. Phan's conference presentation on complementary therapies (which can be viewed here) there was not enough time to address all questions, so Dr. Phan recorded a follow-up podcast to answer all the questions submitted by conference attendees.

If you watch this episode, please let us know what you think at https://www.surveymonkey.com/r/KGB7PKY

CF Community Voices is made possible through grants from Chiesi USA, Genentech, Vertex Pharmaceuticals, Gilead Sciences, and Viatris.

Pseudomonas aeruginosa Diversifies Inside Cells to Form an Adaptive Niche that Resists Antibiotic Treatment – Naren Gajenthra Kumar, BTech, PhD

Dr. Naren G. Kumar, a postdoctoral research scholar at the University of California Berkeley, presents results from CFRI-funded research on characterizing the intracellular diversification of Pseudomonas aeruginosa in chronic lung infections. Findings from experiments suggest that P. aeruginosa undergoes adaptive phenotypic changes in response to the intracellular microenvironment that favor the development of antibiotic-resistant sub-populations. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 31, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Expanding Opportunities for Lung Transplant for Individuals with Cystic Fibrosis – Joseph Pilewski, MD

Dr. Joseph M. Pilewski, Associate Professor of Medicine, Pediatrics, and Clinical and Translational Science at the University of Pittsburgh and Co-director of the Cystic Fibrosis Program at University of Pittsburgh Medical Center, presents on advances in lung transplantation for individuals with cystic fibrosis. His presentation provides an overview of the transplant process - from discussion of prognosis and referral to a transplant center, to transplant evaluation, to listing, transplant surgery and care after transplant – as well as criteria to be a transplant candidate, survival after transplant, and quality of life after transplant. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 31, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

CF Airway Infections: To Treat or Not To Treat? Why and How? – Dao Nguyen, MD.CM, FRCP(C)

Dr. Dao Nguyen, Associate Professor of Medicine at McGill, Clinician Scientist at the Research Institute of the McGill University Health Centre, Physician in the Division of Respirology at the McGill University Health Centre and Founding Director of the McGill Antimicrobial Resistance Centre, reviews the recent advances in our understanding, diagnosis and treatment of CF airway infections, as well as the challenges and remaining questions. Her presentation gives an overview on different microbes, particularly bacteria, ways to diagnose infection, and how to determine whether to treat and what kinds of treatments there are. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Pseudomonas aeruginosa Diversifies Inside Cells to Form an Adaptive Niche that Resists Antibiotic Treatment – Naren Gajenthra Kumar, BTech, PhD (Audio)

Dr. Naren G. Kumar, a postdoctoral research scholar at the University of California Berkeley, presents results from CFRI-funded research on characterizing the intracellular diversification of Pseudomonas aeruginosa in chronic lung infections. Findings from experiments suggest that P. aeruginosa undergoes adaptive phenotypic changes in response to the intracellular microenvironment that favor the development of antibiotic-resistant sub-populations. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 31, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Expanding Opportunities for Lung Transplant for Individuals with Cystic Fibrosis – Joseph Pilewski, MD (Audio)

Dr. Joseph M. Pilewski, Associate Professor of Medicine, Pediatrics, and Clinical and Translational Science at the University of Pittsburgh and Co-director of the Cystic Fibrosis Program at University of Pittsburgh Medical Center, presents on advances in lung transplantation for individuals with cystic fibrosis. His presentation provides an overview of the transplant process - from discussion of prognosis and referral to a transplant center, to transplant evaluation, to listing, transplant surgery and care after transplant – as well as criteria to be a transplant candidate, survival after transplant, and quality of life after transplant. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 31, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

CF Airway Infections: To Treat or Not To Treat? Why and How? – Dao Nguyen, MD.CM, FRCP(C) (Audio)

Dr. Dao Nguyen, Associate Professor of Medicine at McGill, Clinician Scientist at the Research Institute of the McGill University Health Centre, Physician in the Division of Respirology at the McGill University Health Centre and Founding Director of the McGill Antimicrobial Resistance Centre, reviews the recent advances in our understanding, diagnosis and treatment of CF airway infections, as well as the challenges and remaining questions. Her presentation gives an overview on different microbes, particularly bacteria, ways to diagnose infection, and how to determine whether to treat and what kinds of treatments there are. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Partnership in CF Care: Complementary Therapies – Hanna Phan, PharmD, FCCP, FPPA

Dr. Hanna Phan, Clinical Associate Professor in the Department of Clinical Pharmacy at the University of Michigan, reviews some of the commonly used complementary and alternative therapy or medicines (CAM) for CF patients, CAM products’ safety and effectiveness data, considerations in evaluating and discussing available data of products, and recommended best practices of coproducing integrative care in CF. This presentation was part of CFRI's Virtual 35th National CF Education Conference on July 30, 2022.

CFRI's 35th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.